Program Information
Rotating Shield High Dose Rate Brachytherapy with 153Gd and 75Se Isotopes
M Renaud1*, R Flynn2 , J Seuntjens3 , S Enger4 , (1) McGill University, Montreal, Quebec, (2) University of Iowa Hospitals and Clinics, Iowa City, IA, (3) McGill University, Montreal, Quebec, (4) McGill University, Montreal, Quebec
Presentations
TU-AB-201-8 (Tuesday, July 14, 2015) 7:30 AM - 9:30 AM Room: 201
Purpose: To introduce rotating shield brachytherapy (RSBT) for different cancer sites with ¹⁵³Gd and ⁷⁵Se isotopes. RSBT is a form of intensity modulated brachytherapy, using shielded rotating catheters to provide a better dose distribution in the tumour while protecting healthy tissue.
Methods: BrachySource, a Geant4-based Monte Carlo dose planning system was developed for investigation of RSBT with ¹⁵³Gd and ⁷⁵Se for different cancer sites. Dose distributions from ¹⁵³Gd, ⁷⁵Se and ¹⁹²Ir isotopes were calculated in a 40 cm radius water phantom by using the microSelectron-v2 source model. The source was placed inside a cylindrical platinum shield with 1.3 mm diameter. An emission window coinciding with the active core of the source was created by removing half (180°) of the wall of the shield. Relative dose rate distributions of the three isotopes were simulated. As a proof of concept, a breast cancer patient originally treated with Mammosite was re-simulated with unshielded ¹⁹²Ir and shielded ¹⁵³Gd.
Results: The source with the lowest energy, ¹⁵³Gd, decreased the dose on the shielded side by 91%, followed by ⁷⁵Se and ¹⁹²Ir with 36% and 16% reduction at 1 cm from the source. The breast cancer patient simulation showed the ability of shielded ¹⁵³Gd to spare the chest wall by a 90% dose reduction when only one emission window angle is considered. In this case, fully covering the PTV would require more delivery angles and the chest wall dose reduction would be less, however, the simulation demonstrates the potential of shielded ¹⁵³Gd to selectively isolate organs at risk.
Conclusion: Introducing ¹⁵³Gd and ⁷⁵Se sources combined with RSBT will allow escalation of dose in the target volume while maintaining low doses in radiation sensitive healthy tissue. Tailoring treatments to each individual patient by treating all parts of the tumour without over-irradiation of normal tissues will be possible.
Funding Support, Disclosures, and Conflict of Interest: The author acknowledges partial support by the CREATE Medical Physics Research Training Network grant of the Natural Sciences and Engineering Research Council (Grant number: 432290), and the Quebec Fonds de recherche Nature et Technologies.
Contact Email: